Search results for "Crohn's Disease"

QSAR methods for the discovery of new inflammatory bowel disease drugs

2013

Inflammatory bowel disease (IBD) represents an important class of chronic gastrointestinal tract disease. And although there are already several useful treatments to reduce and control the symptoms, there is still no cure. One drug discovery technique used is the computer-aided (in silico) discovery approach which has largely demonstrated efficacy. Computational techniques, when used in combination with traditional drug discovery methodology, greatly increase the chance of drug discovery in a sustainable and economical fashion.This review aims to provide the most recent and important advances of in silico IBD drug discovery. While this review is mainly focused on QSAR methods, especially th…

Shikonin promotes intestinal wound healing in vitro via induction of TGF-β release in IEC-18 cells

2013

The intestinal barrier is a complex system with a dynamic structure that is designed for the maintenance of homeostasis in healthy individuals. Ulcerative colitis, one of the main manifestations of inflammatory bowel disease, is characterized by an inadequate and delayed wound healing. Shikonin, the active principle in the root of Lithospermum erythrorhizon, has demonstrated its ability to attenuate dextran sulfate sodium-induced ulcerative colitis in mice. Moreover, the root of L. erythrorhizon has been used in traditional Chinese medicine for treatment of burns, anal ulcers, hemorrhoids and skin wounds. However, the effect of shikonin on intestinal wound healing is unknown. Using an in vi…

Mouse models of inflammatory bowel disease.

2007

Animal models of intestinal inflammation are indispensable for our understanding of the pathogenesis of Crohn disease and Ulcerative colitis, the idiopathic forms of inflammatory bowel disease in humans. The clinical appearance of human IBD is heterogeneous, a fact that is also reflected by the steadily increasing number of mouse strains displaying IBD like intestinal alterations. The analysis of these models together with genetic studies in humans greatly enhanced our insights into immunoregulatory processes in the gut and led to the generally accepted hypothesis that a deregulated immune response against components of the intestinal microbiota is critically involved in IBD pathophysiology…

An unusual presentation of T-lymphoma in a Crohn's 4 disease patient treated with combo therapy: We are 5 willing to take a risk of serious adverse e…

2012

Comparing medical treatment in Crohn's disease

2013

The drugs available for inflammatory bowel disease are aminosalicylates, antibiotics, steroids, immunosuppressors and biologics. The effectiveness of these drugs has been evaluated in many randomized clinical trials, mainly versus placebo. Few studies have been conducted comparing the different drugs among themselves, owing to the methodological problems raised by comparative trials, such as sample size and blindness. This review focuses mainly on the randomized clinical trials that have compared different treatments. Of course comparisons are mainly between drugs used in a particular setting (mild, moderate and severe disease). However, on many occasions there is no homogeneity in these cl…

Orthopaedic experience on inflammatory bowel disease (Lesniowski-Crohn's disease and ulcerative colitis)

2010

Inflammatory Bowel Diseasae (IBD)is a group of inflammatory conditions of the gastrointestinal tract. The major types of IBD are Lesniowski-Crohn's disease (L-CD) and ulcerative colitis (UC). IBD sometimes presents with arthritic manifestations. The peripheral arthitis is a problem for the orthopaedist and the physiatrist. The Authors retrospectively reviewed 65 sicilian patients with IBD (38 with UC, 27 with L-CD) over a period of 5 years. All patients underwent clinical examinations, laboratory and imaging studies, and were screened for the presence of the rheumatoid factor. All patients also attended eight to ten 50-minutes sessions of physioterapy over a six-week period. REsults: 38 pat…

BONE LOSS I INFLAMMATORI BOWEL DISEASE: OUR MULTICENTRIC STUDY

2011

Patients with inflammatory bowel disease are at increased risk of developing disorder in bone and mineral metabolism. The study was aimed to determine if inflammatory bowel disease (IBD) is a risk factor for osteoporosis in 103 adult patients. We included 103 IBD patients, 67 patients with Crohn's disease (CD) and 36 with ulcerative colitisi (UC). Bone mineral density was measured by dual-energy X-ray absorptiometry. we used T score to express bone loss (osteopenia: -25SD 2 years) and active disease would be risk of bone mineral loss in IBD.

CHRONIC INFLAMMATORY BOWEL DISEASES IN PATIENTS WITH ORTHOPEDIC MANIFESTATION. COMPARISON WITH THE DATA REPORTED IN INTERNATIONAL LITERATURE

2012

In Inflammatory Bowel Disease (IBD) the suspected etiological cause is a dysregulation of the intestinal immune system, in which it is possible to determine a cross-like immune reactivity against the resident microbiota; this mechanism explains the exsistence of Lesnioski-Chron's disease, a variant of IBD in which patients manifest osteoarticular problems that may also be the primary manifestation of the disease. The aim of this study was to compare some cases encountered by our research group at the University of Palermo with others reported in international literature on osteoarticular manifestations in IDB.

TARGETED THERAPIES FOR INFLAMMATORY BOWEL DISEASES AND COLORECTAL CANCER: AN INCREASING NEED FOR MICROBIOTA-INTESTINAL MUTUALISM

2015

The involvement of intestinal microbiota and dysbiosis in the pathogenesis for inflammatory bowel disease (IBD) and colorectal cancer (CRC) is a well-established factto be taken into real consideration when developing targeted therapies. This review aims to depict how advances in our understanding of the role of intestinal flora in the pathogenesis of IBD and CRC are shaping up the therapeutic protocols of their management. It is demonstrated of their management. It is demostrated that there is a circadian regulation of colocyte gene expression in response to microbiota. Dysbiosis leading to a decrease in microbiome biodiversity is also described in IBD patients in IBD patients whereby thic…

CROHN'S DISEASE AND EXTRAINTESTINAL GRANULOMATOUS LESIONS

2018

Crohn's disease (CD) is an inflammatory bowel disease with a multifactorial etiology. Clinical features include mucosal erosion, diarrhea, weight loss and other complications such as formation of granuloma. in CD, granuloma is a non-neoplastic epithelioid lesio, formed by a compact aggregate of histiocytes with the absence of a central necrosis, however, the correlation amomg CD and the formation of granulomas is unknown. Many casesof granulomas in the extracellular site, related to Cd, have been reported in the literature. These granulomas, at times, rapresented the only visible manifestation of the pathology. extra intestinal granuloma have been found on ovaries, lungs, male genitalia, fe…